Comparison

Scleral lenses vs amniotic membrane

Both are used when the surface of the eye is badly damaged. One is a healing treatment applied for days or weeks, the other is a device worn every day. They often come at different stages of the same condition.

By the Scleral Lens Team · Updated October 2, 2026 · 13 published sources cited

The short answer

Amniotic membrane is a thin layer of donated human tissue placed over the eye to calm inflammation and help the surface heal. It's a short-term treatment, sometimes stitched or glued in place and sometimes held by a ring like a large contact lens. A scleral lens is a long-term device that keeps the cornea under saline and can also restore vision. Amniotic membrane is often used for acute injury or a wound that won't heal. Scleral lenses are often used for ongoing protection afterward. Your eye doctor will recommend the right step.

Key points

  • Amniotic membrane is a biological healing treatment, used for days to weeks.
  • Scleral lenses are a daily device for long-term protection and vision.
  • In acute Stevens-Johnson syndrome, early membrane treatment is linked to better long-term outcomes.
  • Ring-mounted membranes are convenient but cover less of the eye and can blur vision while in.
  • The two are often used one after the other, not instead of each other.

What each one is

Amniotic membrane is a thin sheet of donated human tissue. Used on the eye, it has anti-inflammatory and anti-scarring effects and supports healing of the surface. It’s used in acute conditions such as chemical burns and Stevens-Johnson syndrome, and in chronic ones such as persistent epithelial defects (spots on the cornea that won’t heal) and dry eye.[1]

It can be applied in different ways. In surgery, it can be stitched or glued over the eye’s surface. Without stitches, it can be mounted in a ring that sits on the eye like a large contact lens, or held under a bandage contact lens, which allows treatment in the office.[4][8] The 2025 international TFOS DEWS III report lists amniotic membrane among advanced options for severe or treatment-resistant dry eye.[7]

A scleral lens is a large rigid lens that rests on the white of the eye and vaults over the cornea, holding a reservoir of saline against it. It doesn’t add anything biological. It protects the cornea from drying and from the eyelids, and it can improve vision on a damaged or irregular surface. It’s worn daily, for as long as it helps.

Side by side

Amniotic membrane[2][4] Scleral lens[12]
What it is Donated human tissue placed on the eye A custom rigid lens filled with saline
How it helps Biological effects that calm inflammation and support healing Keeps the cornea under fluid and shielded from the eyelids
How long A course of treatment, typically days to weeks Worn daily, long term
How it’s applied Surgery (stitched or glued) or in the office (ring or under a soft lens) Inserted and removed by you every day after fitting
Vision while in place Can be blurred, depending on the product[6] Often improved
Main uses Acute injury and inflammation, wounds that won’t heal Chronic dryness, exposure, irregular or scarred corneas
Main risks Pain, a displaced membrane or lost ring, sterile inflammation, rarely perforation Handling difficulty, fogging, infection risk shared with all contact lenses
Evidence Mostly observational studies Mostly case series from specialty clinics

What the research on amniotic membrane shows

  • Healing slow wounds. A 2025 systematic review of 14 studies of stitch-free membrane for corneal surfaces that were slow to heal found complete healing in 64.4% of patients, taking from 3 to 43 days. Adverse events were uncommon: pain in 2.9%, a displaced membrane or lost ring in 1.7%, sterile infiltrates in 1.8%, and corneal perforation in 0.6%.[2]
  • Dry eye. A multi-center retrospective study of 89 eyes with moderate to severe dry eye treated with a ring-held frozen membrane for 2 to 7 days found improved dry eye severity scores at one week, one month and three months.[3] Several of the authors were employed by or received fees from the product’s manufacturer, and there was no comparison group.
  • Acute Stevens-Johnson syndrome. A 2026 systematic review of 54 studies found that membrane treatment in the acute phase, ideally within 2 weeks of symptoms starting, was followed by vision of 20/50 or better in most patients and low rates of long-term eye complications. Membrane applied in the chronic phase gave some symptom relief.[5] Another review concluded that ring-held membranes don’t cover the whole eye surface in acute Stevens-Johnson syndrome and should be used only alongside fuller coverage.[4]
  • Deep wounds. A review comparing bandage lenses and amniotic membrane found membrane more effective for deep ulcers and nerve-related (neurotrophic) disease.[8]
  • Vision during treatment. A lab study measured how much different membrane products blurred a test image and found wide differences, with thicker membranes generally blurring more.[6]

What the research on scleral lenses shows

  • Chronic ocular surface disease. In a study of 49 people with severe ocular surface disease, mostly Stevens-Johnson syndrome (71% of eyes), 53% of eyes gained two or more lines of vision, and 8 of 15 eyes with active epithelial defects healed. 92% of patients reported better quality of life.[9]
  • Defects that won’t heal. With supervised overnight wear and an antibiotic in the lens, defects healed in 17 of 20 eyes.[11]
  • Long term. In a five-year follow-up of one scleral device, 64% of people treated for ocular surface disease were still wearing it.[13]

How they fit together

In practice, these treatments are often used in sequence. In an early series of scleral lens treatment for non-healing defects, one eye that didn’t heal with the lens went on to heal after multiple amniotic membrane grafts.[10] In Stevens-Johnson syndrome, membrane treatment is aimed mainly at the acute phase, while scleral lenses are used for the long-term surface problems that can follow; Stevens-Johnson syndrome was the most common reason for fitting in the scleral lens series above.[5][9] See our page on Stevens-Johnson syndrome.

Questions to ask your eye doctor

  • Is this a problem that needs healing now, ongoing protection, or both?
  • Would amniotic membrane be applied in the office or in surgery? How long would it stay on?
  • How much will I be able to see while it’s in?
  • After the surface heals, would a scleral lens help keep it healthy?
  • If I already wear a scleral lens, should I stop while I’m being treated?

See also scleral lenses vs bandage soft lenses, and our pages on persistent epithelial defects and severe dry eye.

Common questions

Where does amniotic membrane come from?

It's donated human tissue, processed for medical use. It's prepared and preserved in different ways, which is why there are several products, and the method can affect how it performs.

Can I see while an amniotic membrane ring is in?

It depends on the product. A lab study found that membrane products differ widely in how much they blur, with thicker ones generally blurring more. Ask your eye doctor what to expect with the product they use.

Can I go back to my scleral lens after amniotic membrane treatment?

Often, once the surface has healed and your eye doctor clears you. Ask both your corneal doctor and your fitter, as the lens fit may need checking if the shape or surface of the eye has changed.

Which is better for dry eye?

They're used differently. A ring-held membrane is a short course of treatment that may improve the surface for weeks to months. A scleral lens is worn every day for ongoing protection. International dry eye guidance places amniotic membrane among advanced options for severe or treatment-resistant cases.

Keep reading

Scleral lenses vs bandage soft contact lenses

A bandage soft contact lens is a soft lens your eye doctor places on the eye to protect a damaged cornea from the eyelids and ease pain while it heals. It's quick and widely available. A scleral lens vaults over the cornea and keeps it under a layer of saline, which can help when the eye is too dry or exposed for a soft lens to work, including some non-healing defects. Scleral lenses used for healing are a specialist treatment under close supervision. Your eye doctor decides which fits your eye.

Scleral lenses vs autologous serum eye drops

Autologous serum drops are eye drops made from your own blood. They're meant to resemble natural tears more closely than artificial tears do and to support healing of the eye's surface. A scleral lens doesn't treat the surface with anything. It holds a pool of saline over the cornea so it stays wet and shielded from the eyelids all day, and it can also sharpen vision. Serum is a drop routine. A scleral lens is a device to handle. Your eye doctor will decide which, or both, makes sense.

Scleral lenses vs punctal plugs

Punctal plugs are tiny devices placed in the tear drains of the eyelids so your own tears stay on the eye longer. They're quick to put in and can be removed. A scleral lens holds a reservoir of saline over the cornea all day, so it doesn't depend on how many tears you make, and it can also sharpen vision. Plugs are usually tried earlier. Scleral lenses are usually for dry eye that hasn't responded to other treatments. Many people use both. Your eye doctor will advise.

Scleral lenses for ocular surface disease referrals

Scleral lenses protect the ocular surface by holding a reservoir of non-preserved saline against the cornea and shielding it from lid shear and evaporation. They are a step 3 therapy in TFOS DEWS II, generally used after lubricants, anti-inflammatory therapy, and punctal occlusion, and often alongside them. Outcome data are strongest for exposure, neurotrophic keratopathy, and ocular GVHD, and weaker for dry eye without corneal involvement. Continuation is lower than in irregular cornea, so set expectations.

Sources

  1. Hopkinson A, Figueiredo FC. A narrative review of amniotic membrane transplantation in ocular surface repair: unveiling the immunoregulatory pathways for timely intervention. Ophthalmol Ther. 2025;14(7):1385-1409. doi:10.1007/s40123-025-01143-w pubmed.ncbi.nlm.nih.gov
  2. Natalia MER, Susiyanti M. The efficacy of sutureless amnion membrane transplantation for corneal epithelialization in delayed corneal healing: a systematic review. Korean J Ophthalmol. 2025;39(3):288-299. doi:10.3341/kjo.2025.0004 pubmed.ncbi.nlm.nih.gov
  3. McDonald M, Janik SB, Bowden FW, et al. Association of treatment duration and clinical outcomes in dry eye treatment with sutureless cryopreserved amniotic membrane. Clin Ophthalmol. 2023;17:2697-2703. doi:10.2147/OPTH.S423040 pubmed.ncbi.nlm.nih.gov
  4. Paris J, Macri C, Almater AI, Slattery J, Selva D. Amniotic membrane transplantation techniques in acute ocular Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review. Ocul Surf. 2025;38:337-358. doi:10.1016/j.jtos.2025.10.002 pubmed.ncbi.nlm.nih.gov
  5. Pickens ML, Pickens JL, Duffy S, Bernal MD, Culotta N. Ocular outcomes of amniotic membrane transplantation in acute and chronic Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review. Int Ophthalmol. 2026;46(1):353. doi:10.1007/s10792-026-04242-0 pubmed.ncbi.nlm.nih.gov
  6. Lee BJ, Tsao J, Afshari NA. Comparative analysis of optical properties in amniotic membrane products. Int Ophthalmol. 2025;45(1):474. doi:10.1007/s10792-025-03805-x pubmed.ncbi.nlm.nih.gov
  7. Jones L, Craig JP, Markoulli M, et al. TFOS DEWS III: Management and Therapy. Am J Ophthalmol. 2025;279:289-386. doi:10.1016/j.ajo.2025.05.039 pubmed.ncbi.nlm.nih.gov
  8. AlShammari AZAM, Khouqeer Z, Medani S, Elbashir Abdelgadir Z, Alnefaie Z. The role of bandage contact lenses versus amniotic membrane in corneal wound healing: a systematic review. Cureus. 2025;17(7):e87260. doi:10.7759/cureus.87260 pubmed.ncbi.nlm.nih.gov
  9. Romero-Rangel T, Stavrou P, Cotter J, Rosenthal P, Baltatzis S, Foster CS. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol. 2000;130(1):25-32. doi:10.1016/S0002-9394(00)00378-0 pubmed.ncbi.nlm.nih.gov
  10. Rosenthal P, Cotter JM, Baum J. Treatment of persistent corneal epithelial defect with extended wear of a fluid-ventilated gas-permeable scleral contact lens. Am J Ophthalmol. 2000;130(1):33-41. doi:10.1016/S0002-9394(00)00379-2 pubmed.ncbi.nlm.nih.gov
  11. Lim P, Ridges R, Jacobs DS, Rosenthal P. Treatment of persistent corneal epithelial defect with overnight wear of a prosthetic device for the ocular surface. Am J Ophthalmol. 2013;156(6):1095-1101. doi:10.1016/j.ajo.2013.06.006 pubmed.ncbi.nlm.nih.gov
  12. Schornack MM, Pyle J, Patel SV. Scleral lenses in the management of ocular surface disease. Ophthalmology. 2014;121(7):1398-1405. doi:10.1016/j.ophtha.2014.01.028 pubmed.ncbi.nlm.nih.gov
  13. Agranat JS, Kitos NR, Jacobs DS. Prosthetic replacement of the ocular surface ecosystem: impact at 5 years. Br J Ophthalmol. 2016;100(9):1171-1175. doi:10.1136/bjophthalmol-2015-307483 pubmed.ncbi.nlm.nih.gov

Last updated October 2, 2026. Found an error or a newer study? Let us know and we'll correct the page.